Beacon says gene therapy succeeds in key trial of rare eye disease XLRP

Beacon Therapeutics has succeeded in a genetic eye disease where large drugmakers including Johnson & Johnson and Biogen have failed. On Monday, Beacon said its gene therapy for X-linked retinitis pigmentosa (XLRP) passed a Phase ...